254 related articles for article (PubMed ID: 30554762)
41. Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.
Kohli MA; Farkouh RA; Maschio MJ; McGarry LJ; Strutton DR; Weinstein MC
Health Aff (Millwood); 2015 Jul; 34(7):1234-40. PubMed ID: 26135209
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.
Stoecker C; Hampton LM; Link-Gelles R; Messonnier ML; Zhou F; Moore MR
Pediatrics; 2013 Aug; 132(2):e324-32. PubMed ID: 23821695
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Giglio N; Gentile A; Jimenez SG; Jáuregui B; Clark AD; Diosque M; Vizzotti C
Vaccine; 2011 Jul; 29(31):4963-72. PubMed ID: 21621575
[TBL] [Abstract][Full Text] [Related]
45. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
46. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
[TBL] [Abstract][Full Text] [Related]
47. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
48. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach.
Wu DB; Chang CJ; Huang YC; Wen YW; Wu CL; Fann CS
Value Health; 2012; 15(1 Suppl):S15-9. PubMed ID: 22265061
[TBL] [Abstract][Full Text] [Related]
50. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
Lara C; De Graeve D; Franco F
Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
[TBL] [Abstract][Full Text] [Related]
52. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
[TBL] [Abstract][Full Text] [Related]
53. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
[TBL] [Abstract][Full Text] [Related]
54. Global invasive bacterial vaccine-preventable diseases surveillance--2008-2014.
Murray J; Agócs M; Serhan F; Singh S; Deloria-Knoll M; O'Brien K; Mwenda JM; Mihigo R; Oliveira L; Teleb N; Ahmed H; Wasley A; Videbaek D; Wijesinghe P; Thapa AB; Fox K; Paladin FJ; Hajjeh R; Schwartz S; Van Beneden C; Hyde T; Broome C; Cherian T;
MMWR Morb Mortal Wkly Rep; 2014 Dec; 63(49):1159-62. PubMed ID: 25503919
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
56. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.
Agudelo CI; Castañeda-Orjuela C; Brandileone MCC; Echániz-Aviles G; Almeida SCG; Carnalla-Barajas MN; Regueira M; Fossati S; Alarcón P; Araya P; Duarte C; Sánchez J; Novas M; Toraño-Peraza G; Rodríguez-Ortega M; Chamorro-Cortesi G; Kawabata A; García-Gabarrot G; Camou T; Spadola E; Payares D; Andrade AL; Di Fabio JL; Castañeda E;
Lancet Infect Dis; 2021 Mar; 21(3):405-417. PubMed ID: 32986996
[TBL] [Abstract][Full Text] [Related]
57. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
Prasad N; Stoecker C; Xing W; Cho BH; Leidner AJ; Kobayashi M
Vaccine; 2023 May; 41(18):2914-2921. PubMed ID: 37012118
[TBL] [Abstract][Full Text] [Related]
58. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
60. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States.
Hu T; Weiss T; Owusu-Edusei K; Petigara T
J Med Econ; 2020 Dec; 23(12):1653-1660. PubMed ID: 33084447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
